Nektar Therapeutics
NASDAQ:NKTRBiotechnology
-$1.24 today
- Market cap
- $987.44M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
Volume 0.71M
Average 1.00M
NKTR EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Nektar TherapeuticsNASDAQ: NKTR
EPS (Basic) · Q2 FY2026 · quarter ended Jun 2026
EPS (Basic) remains negative
Q2 FY2026 EPS (Basic) was -$1.23, compared with -$2.95 a year earlier. Trailing-twelve-month EPS (Basic) was -$6.7.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 12 analysts of -$7.35 (+24.4%) for the fiscal year ending Dec 2026, a step up from the -12.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$1.23+32.4% QoQ
- Last fiscal yearDec 2025
- -$9.73-12.1% YoY
- LTMJun 2026
- -$6.7+23.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +58.3% | -10.7% | -69.0 pp |
| 1 year | -12.1% | +24.4% | +36.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (9.73) USD
- Year-over-year change
- -12.1%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.73) | -12.1% |
| FY2024 | 2024-12-31 | (8.68) | +60.2% |
| FY2023 | 2023-12-31 | (21.79) | +26.2% |
| FY2022 | 2022-12-31 | (29.51) | +31.2% |
| FY2021 | 2021-12-31 | (42.90) | — |
EPS (Basic) vs competitors
How NKTR compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +23.1% is the 2nd highest of 10, against a peer median of +12.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $0.37 USD | +335.9% | — | |
| LTM Mar 2026 | -$0.37 USD | +12.9% | — | |
| FY2025 | -€0.53 EUR | +13.1% | — | |
| LTM Mar 2026 | -$0.55 USD | +14.1% | — | |
| LTM Mar 2026 | -$1.1 USD | -23.6% | — | |
| LTM Mar 2026 | -$1.28 USD | -12.9% | — | |
| LTM Mar 2026 | -€1.71 EUR | -1314.4% | — | |
| LTM Jun 2026 | -$2.17 USD | +13.5% | — | |
| LTM Jun 2026 | -$3.93 USD | -20.6% | — | |
| LTM Jun 2026 | -$6.7 USD | +23.1% | — | |
| LTM Jun 2024 | -$7.08 USD | — | — | |
| Peer median (excluding NKTR) | — | +12.9% | — | |
Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 101.91M | 92.06M | 90.12M | 98.43M | 55.23M |
| Cost of Revenue | 24.9M | 21.64M | 36.64M | 30.69M | 0 |
| Gross Profit | 77.01M | 70.42M | 53.48M | 67.74M | 55.23M |
| Gross Margin | 75.6% | 76.5% | 59.3% | 68.8% | 100.0% |
| Research & Development | 400.27M | 218.32M | 114.16M | 120.91M | 117.33M |
| Selling, General & Admin | 122.84M | 92.33M | 77.42M | 76.75M | 68.67M |
| Operating Expenses | 523.11M | 310.66M | 190.9M | 172.94M | 186M |
| Depreciation & Amortization | 14.15M | 12.2M | 7.82M | 4.39M | 1.03M |
| EBITDA | (461.82M) | (323.87M) | (243.11M) | (86.7M) | (137M) |
| EBITDA Margin | -453.2% | -351.8% | -269.8% | -88.1% | -248.1% |
| Operating Income | (446.1M) | (240.24M) | (137.43M) | (105.2M) | (130.77M) |
| Operating Margin | -437.8% | -261.0% | -152.5% | -106.9% | -236.8% |
| Interest Income | 2.73M | 6.78M | 19.01M | 14.5M | 10.44M |
| Interest Expense | 47.31M | 28.91M | 25.33M | 28.11M | 26.18M |
| Other Income / Expenses | (77.18M) | (124.75M) | (138.83M) | (14M) | (33.44M) |
| Income Before Tax | (523.28M) | (364.98M) | (276.26M) | (119.2M) | (164.21M) |
| Pre-Tax Margin | -513.5% | -396.5% | -306.5% | -121.1% | -297.3% |
| Income Tax Expense | 557K | 3.22M | (200K) | (239K) | (138K) |
| Net Income | (523.84M) | (368.2M) | (276.06M) | (118.96M) | (164.08M) |
| Net Margin | -514.0% | -400.0% | -306.3% | -120.9% | -297.1% |
| EPS (Basic) | (42.90) | (29.51) | (21.79) | (8.68) | (9.73) |
| EPS (Diluted) | (42.90) | (29.51) | (21.79) | (8.68) | (9.73) |
| Weighted Avg Shares | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M |
| Weighted Avg Shares (Diluted) | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M |
Nektar Therapeutics
NASDAQ:NKTR
Intrinsic Alpha fair value
Locked
Current Price
$34.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.